% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{vanderEnde:155720,
author = {van der Ende, Emma L and Morenas-Rodriguez, Estrella and
McMillan, Corey and Grossman, Murray and Irwin, David and
Sanchez-Valle, Raquel and Graff, Caroline and Vandenberghe,
Rik and Pijnenburg, Yolande A L and Laforce, Robert and Ber,
Isabelle Le and Lleo, Alberto and Haass, Christian and
Suarez-Calvet, Marc and van Swieten, John C and Seelaar,
Harro},
title = {{CSF} s{TREM}2 is elevated in a subset in {GRN}-related
frontotemporal dementia.},
journal = {Neurobiology of aging},
volume = {103},
issn = {0197-4580},
address = {Amsterdam [u.a.]},
publisher = {Elsevier Science},
reportid = {DZNE-2021-00888},
pages = {158.e1 - 158.e5},
year = {2021},
abstract = {Excessive microglial activation might be a central
pathological process in GRN-related frontotemporal dementia
(FTD-GRN). We measured soluble triggering receptor expressed
on myeloid cells 2 (sTREM2), which is shed from
disease-associated microglia following cleavage of TREM2, in
cerebrospinal fluid of 34 presymptomatic and 35 symptomatic
GRN mutation carriers, 6 presymptomatic and 32 symptomatic
C9orf72 mutation carriers and 67 healthy noncarriers by
ELISA. Although no group differences in sTREM2 levels were
observed (GRN: symptomatic (median 5.2 ng/mL, interquartile
range [3.9-9.2]) vs. presymptomatic (4.3 ng/mL [2.6-6.1])
vs. noncarriers (4.2 ng/mL [2.6-5.5]): p = 0.059; C9orf72:
symptomatic (4.3 [2.9-7.0]) vs. presymptomatic (3.2
[2.2-4.2]) vs. noncarriers: p = 0.294), high levels were
seen in a subset of GRN, but not C9orf72, mutation carriers,
which might reflect differential TREM2-related microglial
activation. Interestingly, 2 presymptomatic carriers with
low sTREM2 levels developed symptoms after 1 year, whereas 2
with high levels became symptomatic after >5 years. While
sTREM2 is not a promising diagnostic biomarker for FTD-GRN
or FTD-C9orf72, further research might elucidate its
potential to monitor microglial activity and predict disease
progression.},
keywords = {Adult / Aged / Biomarkers: cerebrospinal fluid / C9orf72
Protein: genetics / Female / Frontotemporal Dementia:
diagnosis / Frontotemporal Dementia: genetics / Heterozygote
/ Humans / Male / Membrane Glycoproteins: cerebrospinal
fluid / Membrane Glycoproteins: metabolism / Microglia:
metabolism / Microglia: physiology / Middle Aged / Mutation
/ Progranulins: genetics / Receptors, Immunologic:
metabolism / Biomarker (Other) / Cerebrospinal fluid (Other)
/ Frontotemporal dementia (Other) / Microglia (Other) /
sTREM2 (Other)},
cin = {AG Haass},
ddc = {610},
cid = {I:(DE-2719)1110007},
pnm = {352 - Disease Mechanisms (POF4-352)},
pid = {G:(DE-HGF)POF4-352},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:33896652},
doi = {10.1016/j.neurobiolaging.2021.02.024},
url = {https://pub.dzne.de/record/155720},
}